Hypertension and heart failure: Diagnosis and management

Current Hypertension Reports

Volumn 8, Issue 3, 2006, Pages 185-190

  Courville, Kevin A ^b   Ventura, Hector O ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FELODIPINE; HYDRALAZINE; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; NITRATE; SPIRONOLACTONE; VERAPAMIL;

AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEALTH CARE PERSONNEL; HEART FAILURE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERTENSION; MEDICAL TECHNOLOGY; MORBIDITY; MORTALITY; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; SURVIVAL TIME; SYMPTOMATOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIASTOLE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33744961759     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0049-0     Document Type: Review

References (47)

1. American Heart Association: Heart Disease and Stroke Statistics 2004 Update. Dallas, TX: American Heart Association; 2003.
2. Mehra MR, Uber PA, Potluri S, Ventura O: Is heart failure with preserved systolic function an overlooked enigma? Curr Cardiol Rep 2002, 4:187-193.
3. Senni M, Redfield MM: Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 2001, 38:1277-1282.
4. Vasan RS, Larson MG, Benjamin EJ, et al.: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33:1948-1955.
5. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995, 26:1565-1574.
6. Redfield MN, Jacobsen SJ, Burnett JC, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of heart failure epidemic. JAMA 2003, 289:194-202.
7. Senni M, Tribouilloy CM, Rodeheffer RJ, et al.: Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999, 159:29-34.
8. Vasan RS, Benjamin EJ, Levy D: Congestive heart failure with normal left ventricular systolic function: clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Inter Med 1996, 156:146-157.
9. Slama M, Susic D, Varagic J, et al.: Diastolic dysfunction in hypertension. Curr Opin Cardiol 2002, 17:368-373.
10. Lloyd-Jones DM, Larson MG, Leip EP, et al.: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106:3068-3072.
11. He J, Ogden LG, Bazzano LA, et al.: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161:996-1002.
12. Kannel WB, Ho K, Thom T: Changing epidemiological features of cardiac failure. Br Heart J 1994; 72:S3-S9.
13. Mandinov L, Eberli FR, Seiler C, et al.: Diastolic heart failure. Cardiovasc Res 2000, 45:813-825.
14. Frohlich ED: Risk mechanisms in hypertensive heart disease. Hypertension 1999, 34:782-789.
15. Fouad-Tarazi FM: Left ventricular diastolic dysfunction in hypertension. Curr Opin Cardiol 1994, 9:551-560.
16. Ventura HO, Loyalka P, Smart FW: Treatment of the hypertensive patient with microvascular angina. Curr Opin Cardiol 1999, 14:370-374.
17. Cohn JN, Johnson G: Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation 1990, 81:48-53.
18. Dunlap SH, Sueta CA, Adams KF: Association of body mass, gender, race with heart failure primarily due to hypertension. J Am Coll Cardiol 1999, 34:1602-1608.
19. Laurent D: Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987, 252:C1-C9.
20. Moncrieff J, Lindsay M, Dunn F: Hypertensive heart disease and fibrosis. Curr Opin Cardiol 2004, 19:326-331.
21. Redfield MM, Jacobsen SJ, Burnett JC, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
22. Levy D, Labib SB, Anderson KM, et al.: Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990, 81:815-820.
23. Otto C: Textbook of Clinical Echocardiography, edn 3. Philadelphia: Elsevier/Saunders; 2004.
24. Krishnaswamy P, Lubien E, Clopton P, et al.: Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001, 111:274-279.
25. Lubien E, DeMaria A, Krishnaswamy P, et al.: Utility of B-natriuretic peptide levels in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002, 105:595-601.
26. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:303-310.
27. Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992, 327:669-677.
28. Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. The US Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
29. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
30. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
31. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
32. Pitt B, Zannad F, Remme WJ, et al.: The effect of spirono-lactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
33. Pitt B, Remme W, Zannad F, Neaton J: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
34. Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. The African-American Heart Failure trial Investigators. N Engl J Med 2004, 351:2049-2057.
35. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507-1513.
36. Ventura HO, Loyalka P, Smart FW: Treatment of the hypertensive patient with microvascular angina. Curr Opin Cardiol 1999, 14: 370-374.
37. Poulsen SH, Jensen SE, Egstrup K: Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. Am Heart J 1999, 138:710-720.
38. Matsubara LS, Matsubara BB, Okoshi MP, et al.: Alterations in myocardial collagen content affect rat papillary muscle function. Am J Physiol Heart Circ Physiol 2000, 279: H1534-H1539.
39. Warner JG Jr, Metzger DC, Kitzman DW et al.: Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999, 33:1567-1572.
40. Diez J, Querejeta R, Lopez B, et al.: Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512-2517.
41. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
42. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003, 362:777-781.
43. Setaro JF, Zaret BL, Schulman DS, et al.: Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990, 66:981-986.
44. Terpstra WF, May JF, Smit AJ, et al.: Long term effects of amlodipine and lisinopril on left ventricular mass and diastolic dysfunction in the elderly, in previously treated hypertensive patients: the ELVERA trial. J Hypertens 2001, 19:303-309.
45. Hopf R, Kaltenbach M: Ten-year results and survival of patients with hypertrophic cardiomyopathy treated with calcium antagonists. Z Kardiol 1987, 76:137-144.
46. Bonow RO, Dilsizian V, Rosing DR, et al.: Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 1985, 72:853-864.
47. Hunt SA, Abraham WT, Chin M, et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 2005, 46:1-82.